Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1480 - A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)

Date

10 Sep 2017

Session

Poster display session

Presenters

Maria Gonzalez

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

M. Gonzalez1, A.M. Menzies2, R. Saw3, J.F. Thompson3, A.J. Spillane4, J. Howle5, O. Nieweg3, K. Shannon3, S. Ch'Ng3, J.F. Stretch6, M.S. Carlino7, A. Guminski8, L. Emmett9, H. Rizos10, R.A. Scolyer11, G.V. Long12

Author affiliations

  • 1 Melanoma Oncology, Melanoma Institute Australia, 2060 - Sydney/AU
  • 2 Melanoma Medical Oncology, Melanoma Institute Australia, Royal North Shore Hospital, The University of Sydney, Sydney/AU
  • 3 Surgical Oncology, Melanoma Institute Australia, University of Sydney, Royal Prince Alfred Hospital, Sydney/AU
  • 4 Surgical Oncology, Melanoma Institute Australia, Royal North Shore Hospital, The University of Sydney, Sydney/AU
  • 5 Surgical Oncology, Westmead Hospital, The University of Sydney, Sydney/AU
  • 6 Surgical Oncology, Melanoma Institute Australia, University of Sydney, Sydney/AU
  • 7 Medical Oncology, Westmead and Blacktown Hospitals, Melanoma Institute Australia, The University of Sydney, Sydney/AU
  • 8 Medical Oncology, Melanoma Institute Australia, Royal North Shore Hospital, The University of Sydney, 2060 - Sydney/AU
  • 9 Nuclear Medicine, St Vincent's Hospital, Sydney/AU
  • 10 Biology, Macquarie University, Sydney/AU
  • 11 Pathology, Melanoma Institute Australia, University of Sydney, Royal Prince Alfred Hospital, Sydney/AU
  • 12 Melanoma Medical Oncology, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney/AU
More

Resources

Abstract 1480

Background

BRAF targeted and CTLA-4/PD-1 immunotherapies have high response rates and improve survival for patients (pts) with metastatic melanoma, however, most still die of this disease. It is hypothesised the activated cytotoxic T cell infiltrate that occurs early during treatment with BRAF/MEK inhibitors is potentiated by adding checkpoint inhibitors, resulting in improved response and survival. While trials combining BRAF/MEK inhibitors and anti-PD-1/L1 antibodies are underway in the metastatic setting, the neoadjuvant setting provides an opportunity to test different treatment schedules in small cohorts of pts. Tissue and blood biomarkers can be drawn at several timepoints and correlated to clinical and pathological endpoints to explore mechanisms of response, biomarkers of efficacy, and to select the best schedules to take forward to larger-scale trials.

Trial design

Eligible pts with BRAF V600 mutant, stage IIIB/C/D, resectable and measurable (RECIST 1.1) metastatic melanoma are evenly assigned to 3 cohorts (n = 60). All pts undergo complete macroscopic resection (RES) at week 12 and receive neoadjuvant therapy for 12 weeks preceding RES, followed by 40 weeks of adjuvant therapy. Cohort 1 receive sequential therapy with D+T for 2 weeks, followed by 4 pembrolizumab (pembro) doses until week 12, and 3 weekly pembro after RES. Cohort 2 receive concurrent D+T and 3 weekly pembro before and after RES. Cohort 3 receive 3 weekly pembro for the entire treatment course. Pembro is given at a flat dose of 200mg. Ultrasound surveillance of known disease areas is undertaken during the neoadjuvant period. Serial CT and FDG PET/CT are used to measure response and exclude progression in the neoadjuvant phase, and to monitor for recurrence during adjuvant and post treatment phases. Blood and tumour samples are collected at baseline, week 1, 4 and 12. The primary endpoint is the complete pathological response rate at RES following 12 weeks of therapy. Secondary endpoints include RECIST response, metabolic response, OS, RFS, safety/tolerability, surgical outcomes, quality of life, as well as biomarker analysis.

Clinical trial identification

NCT02858921

Legal entity responsible for the study

Melanoma Institute Australia

Funding

Merck Sharp & Dohme

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.